welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). This approval represents the first drug approved for the treatment of thyroid eye disease.
The approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non-surgical treatment option,” said Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research.
Tepezza was approved based on the results of two studies (Study 1 and 2) consisting of a total of 170 patients with active thyroid eye disease who were randomized to either receive Tepezza or a placebo.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
The UC San Diego Thyroid Eye ClinicThe University of California (UC) San Di...
Rebecca S. Bahn, MDRebecca S. Bahn is the Professor Emeritu...
A Validated Tool can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ D...Over-activity of the thyroid gland, call...
Charles Sydnor, MDCharles Sydnor began his private ophthal...
Contour Variability in Thyroid Eye Disease With Compressive Optic Neuropathy Treated With Radiation TherapyPurpose: Few studies have evaluated t...
Thyroid Eye Disease and the Role of the TED SpecialistNot all people with thyroid disease have...
Vahab Fatourechi, MDVahab Fatourechi is an endocrinologist-i...